What happened with SUPN today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Supernus Pharmaceuticals’ largest products are Qelbree for attention-deficit/hyperactivity disorder and GOCOVRI for Parkinson’s disease movement complications; together they generate most of its product sales. Wholesalers, distributors and specialty pharmacies buy its medicines and supply pharmacies, hospitals and patients. Cencora, Cardinal Health and McKesson together account for a large majority of product revenue, making these purchasing relationships central to the business.
Supernus also markets ZURZUVAE for postpartum depression with Biogen in the United States. Rather than earning through ordinary product sales alone, Supernus shares the collaboration’s operating profits and losses with Biogen. Royalties and licensing payments supplement its U.S. medicine business.
Supernus owns no commercial manufacturing facilities and depends on outside manufacturers, often single-source suppliers, to produce and package its medicines. Sales also depend on government and private insurers covering the drugs and reimbursing their use. New medicines need regulatory approval before sale, and Supernus cannot promote uses that the FDA has not approved.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Beyond Qelbree growth, Parkinson’s treatments and ZURZUVAE adoption, Supernus depends on Britannia for APOKYN and ONAPGO supply—a company missing from this list.
Biogen and Supernus share equally in the U.S. operating profits and losses of ZURZUVAE, their jointly marketed treatment for postpartum depression. Watch the ZURZUVAE sales Biogen records alongside shared development and selling costs: if those costs exceed net revenue, Supernus must fund half the loss.
Collegium Pharmaceutical, Inc.’s Jornay PM competes with Supernus’s Qelbree for ADHD prescriptions and insurer coverage, although Jornay PM is a stimulant and Qelbree is not. Watch Jornay PM’s prescription demand and coverage agreements, rather than Collegium’s pain-drug business, for clues to the pressure on Qelbree.
Amneal Pharmaceuticals, Inc. pressures Supernus through competing branded Parkinson’s medicines and through its Namzaric generic, whose launch eliminated the royalties Supernus had expected from Namzaric sales.
AbbVie’s Vyalev competes with Supernus’s ONAPGO in advanced Parkinson’s disease and can reduce demand for APOKYN by continuously delivering medicine through a wearable pump. Watch Vyalev uptake for pressure on both ONAPGO sales and patients’ need for APOKYN to treat episodes when their Parkinson’s medication wears off.
Takeda’s Vyvanse competes with Supernus’s Qelbree for ADHD prescriptions and coverage from insurers; Vyvanse’s position with prescribers and payers is the part of Takeda to watch for Qelbree competition.
AYTU BioPharma, Inc.’s Adzenys XR-ODT and Cotempla XR-ODT compete with Supernus’s Qelbree for ADHD patients and prescription coverage, making access to those two medicines the competition to watch.
Biogen Inc. earningsBIIB
Biogen records U.S. sales of ZURZUVAE, and the companies share its operating profit or loss equally; Biogen’s report can show whether the partnership brings Supernus revenue or leaves it funding a loss.
Compare Biogen’s reported U.S. ZURZUVAE sales with the development and selling costs the companies share. Sales that cover those costs would show the partnership contributing to Supernus’s business; if costs exceed net revenue, Supernus must fund half the loss, adding to its cash burden.
ABBVIE INC. earningsABBV
AbbVie’s report can show uptake of its Vyalev wearable pump, which competes with Supernus’s ONAPGO and may reduce patients’ need for APOKYN during Parkinson’s medication “off” episodes.
Look for evidence of Vyalev uptake in AbbVie’s report, including whether it is driving sales growth. Broader uptake would show stronger competition for ONAPGO from continuous pump delivery and could reduce patients’ need for APOKYN during medication “off” episodes; limited uptake would mean less pressure on Supernus through this route.
Supernus Pharmaceuticals, Inc. earningsThis company
Supernus earns mainly from a handful of central nervous system medicines, so this report will show whether growth in newer products can offset generic erosion and falling sales of older drugs.
Compare product sales for Qelbree, GOCOVRI and ONAPGO with sales for Oxtellar XR, Trokendi XR and APOKYN. If the first group grows enough to offset declines in the second, newer demand is taking over; if not, generic erosion and weaker demand for older drugs still weigh on the product mix. Then weigh ZURZUVAE collaboration revenue against shared costs: growing revenue without costs swallowing the contribution would show the partnership adding to the business, while limited contribution alongside heavier costs would show the burden it adds.
